SWISS INNOVATION
PATHELEN® HYBRID
An innovation in medical wound care
PATHELEN® Hybrid is a new microporous silica powder, that adsorbs wound exudate, reducing the healing time of chronic wounds and offers a cost-effective alternative to the current treatment options for wounds.
CASE STUDIES
In recent years, the PATHELEN® HYBRID therapy has been tested on patients in various hospitals and in outpatient wound care and has been continuously developed. A wide variety of exuding wound infections were successfully treated up to the complete formation of granulation tissue. Pathelen® Hybrid does not contain any cytotoxic pharmacological agents and has a purely physical effect.
This is particularly important for the new guideline for the reimbursement of bandages, which will come into force on 01.01.2022.
Successful treatments of MRSA infected wounds
You don’t have an account yet? Request one directly: info@pathelen.com
Access only for medical-pharmaceutical professionals (e.g. physicians, hospital staff, students and academic staff of medical universities, pharmacists) and medical-pharmaceutical institutions. Please send press inquiries to contact@pathelen-hybrid.com
COMPANY
Find out more about us
Pathelen Health Care AG is a Swiss biotech company that, in more than 7 years of research and development, has developed innovative forms of therapy for the treatment and healing of various diseases.
Pathelen Health Care AG has specialized in the therapeutic area of biofilm and pathogenic germs, in particular multi-resistant germs (such as MRSA or A. Baumannii).